NDA Group's figures on USA and EU reflect record year for new drug approvals - despite pandemic

31 March 2021

The NDA Group, a regulatory, drug development and medical device consultancy, has released findings from the eighth annual comparison of drug approvals in the European Union (EU) and the USA.

As well as highlighting the continued differences between the two regions, the NDA Group argues that the figures reflect the need for a global approach to drug development to ensure success across both continents.

The report is based on preliminary research figures distilled from the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) websites in January and February 2021, and found that the positive trend in approvals observed over the last couple of years took a noticeable leap forward in 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK